Endocrinology Research and Practice
Original Article

Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study


Department of Endocrinology and Metabolic Diseases, Erciyes University Faculty of Medicine, Kayseri, TURKEY


Department of Internal Medicine, Akdeniz University Faculty of Medicine, Antalya, TURKEY


Department of Endocrinology and Metabolic Diseases, Hitit University Faculty of Medicine, Çorum, TURKEY


Department of Endocrinology and Metabolic Diseases, Gaziantep University Faculty of Medicine, Gaziantep, TURKEY


Department of Endocrinology and Metabolic Diseases, Ondokuz Mayıs University Faculty of Medicine, Samsun, TURKEY


Clinic of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, TURKEY


Department of Internal Medicine, Yeditepe University Faculty of Medicine, İstanbul, TURKEY


Clinic of Endocrinology, İzmir Bozyaka Training and Research Hospital, İzmir, TURKEY


AstraZeneca Pharmaceuticals, İstanbul, TURKEY


Department of Endocrinology and Metabolic Diseases, Çukurova University Faculty of Medicine, Adana, TURKEY

Endocrinol Res Pract 2021; 25: 202-215
DOI: 10.25179/tjem.2021-81148
Read: 1246 Downloads: 365 Published: 01 June 2021


To evaluate the treatment patterns and associated clinical outcomes in Type 2 diabetes (T2D) patients initiating a second-line glucose-lowering therapy. Material and Methods: This paper presents a preliminary subgroup analysis of the baseline data collected from 536 patients [mean (standard deviation) age: 55.1 (10.0) years, 50.2% were males] in the Turkey arm of global observational DISCOVER study among T2D patients initiating second-line glucose-lowering therapy. Patient demographics, disease (duration, complications) and treatment (type of regimens, modifications) characteristics, hemoglobin A1c (HbA1c), low-density lipoprotein-cholesterol (LDL-C), and systolic blood pressure (BP) target achievement rates and the patient-reported outcomes were recorded at the initiation of second-line therapy. Results: Overall, 11.7% of patients were HbA1c target of <7% at baseline, 62.5% were systolic BP target of <140 mmHg and 21.2% were LDL-C target of <100 mg/dL. Major and minor hypoglycemic events were noted in 5.5% and 10.7% of patients, while macro and microvascular complications in 17.2% and 20.1% of patients, respectively. Metformin monotherapy (47.9%) and metformin+sulfonylurea combination (22.6%) were the two most common first-line therapies. However, insulin (32.3%) was the most commonly prescribed second-line agent. Lifestyle assessment revealed a healthy lifestyle in 50.7% of patients. Conclusion: Our finding revealed a failure to achieve HbA1c, LDL-C, and systolic BP targets and a high rate of diabetes-related complications before initiation of second-line therapy in a significant proportion of Turkish T2D patients. Thus, emphasizing a need for more aggressive risk factor screening and modification at early disease stages and earlier treatment intensification among T2D patients.



EISSN 2822-6135